DNA修复基因胚系突变联合治疗暴露与儿童癌症幸存者后续肿瘤风险
该研究对圣裘德终身队列中4402例儿童癌症幸存者进行全基因组测序,评估6大DNA修复通路127个基因的致病性胚系突变,并结合化疗累积剂量和区域放疗剂量分析后续肿瘤风险。结果显示同源重组基因突变与胸部放疗≥20 Gy或蒽环类第二/三三分位剂量者的后续女性乳腺癌风险升高相关,也与烷化剂第三三分位剂量者的后续肉瘤风险升高相关。
要点
- 同源重组基因突变者后续女性乳腺癌风险升高(RR 3.7)。
- 胸部放疗≥20 Gy且同源重组突变者乳腺癌风险进一步升高(RR 4.4)。
- 烷化剂第三三分位剂量且同源重组突变者后续肉瘤风险显著升高(RR 14.9)。
核心结论
- DNA修复基因致病性胚系突变联合治疗暴露可识别后续肿瘤高风险的儿童癌症幸存者。
- 同源重组基因突变与胸部放疗或蒽环类暴露者的后续女性乳腺癌风险升高相关。
- 同源重组基因突变与高剂量烷化剂暴露者的后续肉瘤风险升高相关。
研究设计与样本
- 研究为圣裘德终身队列幸存者全基因组测序分析,共纳入4402例幸存者。
- 评估6大DNA修复通路127个基因的致病性胚系突变。
- 从医疗记录提取化疗累积剂量和体区特异性放疗剂量。
- 采用多变量分段指数模型估计按突变状态的后续肿瘤相对率及95%CI。
主要发现
- 4402例幸存者中495例(11.2%)发生1269例后续肿瘤。
- 508例(11.5%)幸存者检出98个DNA修复基因中的538个致病性胚系突变。
- 同源重组基因突变与后续女性乳腺癌风险升高相关(RR 3.7;95%CI 1.8–7.7)。
- 胸部放疗≥20 Gy者中同源重组突变与乳腺癌风险升高相关(RR 4.4;95%CI 1.6–12.4)。
- 蒽环类第二或三三分位剂量者中同源重组突变与乳腺癌风险升高相关(RR 4.4;95%CI 1.7–11.4)。
关键数值与推荐
- 同源重组基因突变者后续女性乳腺癌相对率RR 3.7(95%CI 1.8–7.7)。
- 胸部放疗≥20 Gy且同源重组突变者乳腺癌RR 4.4(95%CI 1.6–12.4)。
- 蒽环类第二或三三分位剂量且同源重组突变者乳腺癌RR 4.4(95%CI 1.7–11.4)。
- 烷化剂第三三分位剂量且同源重组突变者肉瘤RR 14.9(95%CI 4.0–38.0)。
- 颈部放疗≥30 Gy且核苷酸切除修复基因突变者甲状腺癌RR 12.9(95%CI 1.6–46.6),统计学意义边缘。
临床怎么用
- 对接受胸部放疗或蒽环类治疗的儿童癌症幸存者,可考虑同源重组基因检测以识别乳腺癌高风险者。
- 对接受高剂量烷化剂治疗的幸存者,可考虑同源重组基因检测以识别肉瘤高风险者。
- 基因检测结果可辅助个体化癌症监测与预防策略制定。
局限性
- 核苷酸切除修复基因突变与颈部放疗后甲状腺癌的关联仅达边缘统计学意义。
- 研究基于圣裘德终身队列幸存者,外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate cancer treatment plus pathogenic germline mutations (PGMs) in DNA repair genes (DRGs) for identification of childhood cancer survivors at increased risk of subsequent neoplasms (SNs). METHODS: Whole-genome sequencing was performed on blood-derived DNA from survivors in the St Jude Lifetime Cohort. PGMs were evaluated in 127 genes from 6 major DNA repair pathways. Cumulative doses of chemotherapy and body region-specific radiotherapy (RT) were abstracted from medical records. Relative rates (RRs) and 95% CIs of SNs by mutation status were estimated using multivariable piecewise exponential models. RESULTS: Of 4,402 survivors, 495 (11.2%) developed 1,269 SNs. We identified 538 PGMs in 98 DRGs (POLG, MUTYH, ERCC2, and BRCA2, among others) in 508 (11.5%) survivors. Mutations in homologous recombination (HR) genes were significantly associated with an increased rate of subsequent female breast cancer (RR, 3.7; 95% CI, 1.8 to 7.7), especially among survivors with chest RT ≥ 20 Gy (RR, 4.4; 95% CI, 1.6 to 12.4), or with a cumulative dose of anthracyclines in the second or third tertile (RR, 4.4; 95% CI, 1.7 to 11.4). Mutations in HR genes were also associated with an increased rate of subsequent sarcoma among those who received alkylating agent doses in the third tertile (RR, 14.9; 95% CI, 4.0 to 38.0). Mutations in nucleotide excision repair genes were associated with subsequent thyroid cancer for those treated with neck RT ≥ 30 Gy (RR, 12.9; 95% CI, 1.6 to 46.6) with marginal statistical significance. CONCLUSION: Our study provides novel insights regarding the contribution of genetics, in combination with known treatment-related risks, for the development of SNs. These findings have the potential to facilitate identification of high-risk survivors who may benefit from genetic counseling and/or testing of DRGs, which may further inform personalized cancer surveillance and prevention strategies.
引用
- Qin N, Wang Z, Liu Q, et al. Pathogenic Germline Mutations in DNA Repair Genes in Combination With Cancer Treatment Exposures and Risk of Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer. J Clin Oncol. 2020. PMID: 32496904. doi:10.1200/JCO.19.02760
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。